Ribociclib
http://dbpedia.org/resource/Ribociclib an entity of type: Thing
Le ribociclib (vendu sous les marques Kisqali et Kryxana), commercialisé par Novartis, est un inhibiteur de la cycline D1/CDK4 et CDK6, et est utilisé pour le traitement de certains types de cancer du sein.
rdf:langString
Ribociclib, comercializado sob a marca Kisqali, é um medicamento inibidor da / e usado no tratamento de alguns tipos de cancro da mama. Está também a ser estudado como tratamento para outros tipos de cancro resistentes a fármacos. Foi desenvolvido pela Novartis e .
rdf:langString
瑞博西利（英語：Ribociclib）商品名擊癌利（KISQALI）是一種CDK4/6抑制劑類型的乳腺癌藥物，由和诺华制药研发。可使用的對象為：賀爾蒙接受體陽性、HER2陰性患者，以及停經後晚期乳腺癌患者。
rdf:langString
Ribociclib, sold under the brand name Kisqali and Kryxana marketed by Novartis, is an inhibitor of cyclin D1/CDK4 and CDK6, and is used for the treatment of certain kinds of breast cancer. Ribociclib is a kinase inhibitor indicated in combination with: an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy; or fulvestrant for the treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy. It is also being studied as a treatment for other drug-resistant cancers. I
rdf:langString
rdf:langString
Ribociclib
rdf:langString
Ribociclib
rdf:langString
Ribociclib
rdf:langString
瑞博西利
xsd:integer
49770483
xsd:integer
1112735149
rdf:langString
EF02
rdf:langString
L01
rdf:langString
Unknown
xsd:integer
23
xsd:integer
1211441
xsd:integer
3545110
xsd:integer
30798107
rdf:langString
DB11730
<second>
115200.0
xsd:integer
69
xsd:integer
30
rdf:langString
as salt
xsd:integer
7
rdf:langString
D10883
rdf:langString
D10979
rdf:langString
Rx-only
rdf:langString
a617008
rdf:langString
Liver
xsd:integer
8
xsd:integer
1
xsd:integer
44631912
rdf:langString
CNCc1cc2cncNc4cccN5CCNCC5
xsd:integer
1
rdf:langString
RHXHGRAEPCAFML-UHFFFAOYSA-N
rdf:langString
LEE 011
rdf:langString
Kisqali
rdf:langString
TK8ERE8P56
rdf:langString
Le ribociclib (vendu sous les marques Kisqali et Kryxana), commercialisé par Novartis, est un inhibiteur de la cycline D1/CDK4 et CDK6, et est utilisé pour le traitement de certains types de cancer du sein.
rdf:langString
Ribociclib, sold under the brand name Kisqali and Kryxana marketed by Novartis, is an inhibitor of cyclin D1/CDK4 and CDK6, and is used for the treatment of certain kinds of breast cancer. Ribociclib is a kinase inhibitor indicated in combination with: an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy; or fulvestrant for the treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy. It is also being studied as a treatment for other drug-resistant cancers. It was developed by Novartis and Astex Pharmaceuticals. Ribociclib is currently the only CDK4/6 inhibitor with a proven benefit on overall survival across all three Phase III trials of the MONALEESA clinical program with different endocrine therapy partners, regardless of menopausal status or line of therapy. The European Society of Medical Oncology (ESMO) assigned the highest score on the 'Magnitude of Clinical Benefit Scale' for Kisqali.
rdf:langString
Ribociclib, comercializado sob a marca Kisqali, é um medicamento inibidor da / e usado no tratamento de alguns tipos de cancro da mama. Está também a ser estudado como tratamento para outros tipos de cancro resistentes a fármacos. Foi desenvolvido pela Novartis e .
rdf:langString
瑞博西利（英語：Ribociclib）商品名擊癌利（KISQALI）是一種CDK4/6抑制劑類型的乳腺癌藥物，由和诺华制药研发。可使用的對象為：賀爾蒙接受體陽性、HER2陰性患者，以及停經後晚期乳腺癌患者。
rdf:langString
Ribociclib
rdf:langString
S4
rdf:langString
Rx-only
rdf:langString
Rx-only
rdf:langString
~70%
xsd:nonNegativeInteger
15382
rdf:langString
Kisqali
xsd:string
1211441-98-3
xsd:string
3545110
xsd:string
DB11730
xsd:string
TK8ERE8P56
xsd:string
D10883
D10979
xsd:string
a617008
xsd:string
44631912